NDC 68083-596-01 - Vancomycin Hydrochloride
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 68083-596
- Requested NDC
- 68083-596-01
- Package NDCs from labels
- 68083-596-01, 68083-596-10
- Manufacturer
- Gland Pharma Limited
- Effective date
- 2025-04-24
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Vancomycin Hydrochloride - Gland Pharma Limited | Gland Pharma Limited | 2025-04-24 | Human Prescription Drug Label |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 68083-596-01 | Vancomycin Hydrochloride | 1 in 1 VIAL, SINGLE-DOSE | INJECTION, POWDER, LYOPHILIZED, | 1 | 4 | |
| 68083-596-10 | Vancomycin Hydrochloride | 10 in 1 CARTON | INJECTION, POWDER, LYOPHILIZED, | 10 | 4 |
DailyMed Dashboard NDC Coverage#
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Vancomycin Hydrochloride | VANCOMYCIN HYDROCHLORIDE | Fresenius Kabi USA, LLC | 0713a847-a334-4b73-af22-343aa06621b9 | 2023-02-07 | Warnings, Adverse reactions | 71WO621TJD |
| Vancomycin Hydrochloride | VANCOMYCIN HYDROCHLORIDE | Fresenius Kabi, LLC | 8a35ebee-8650-4ef5-84f5-ab9b55d9bc19 | 2022-12-02 | Warnings, Adverse reactions | 71WO621TJD |
| Vancomycin Hydrochloride | VANCOMYCIN HYDROCHLORIDE | Fresenius Kabi, LLC | 418c3c6a-d08d-448c-89c9-54e558c1ce16 | 2022-12-02 | Warnings, Adverse reactions | 71WO621TJD |
| Vancomycin Hydrochloride | VANCOMYCIN HYDROCHLORIDE | BluePoint Laboratories | f28e3c2b-ae31-4c2a-8178-53962b7b213c | 2022-09-22 | Warnings, Adverse reactions | 71WO621TJD |
| VANCOMYCIN HYDROCHLORIDE | VANCOMYCIN HYDROCHLORIDE | Camber Pharmaceuticals, Inc. | 3f5dacea-af40-4103-b128-c5e0c0c52fa1 | 2022-07-20 | Warnings, Adverse reactions | 71WO621TJD |
| Vancomycin Hydrochloride | VANCOMYCIN HYDROCHLORIDE | Hikma Pharmaceuticals USA Inc. | 86950e7c-0114-47e9-8891-e09e595c48c3 | 2022-02-25 | Warnings, Adverse reactions | 1807518 |
| Vancomycin Hydrochloride | VANCOMYCIN HYDROCHLORIDE | Hikma Pharmaceuticals USA Inc. | cae9e5f3-b89a-4a7f-93f7-9471c74a3559 | 2021-12-07 | Warnings, Adverse reactions | 71WO621TJD |
| Vancomycin Hydrochloride | VANCOMYCIN HYDROCHLORIDE | Fresenius Kabi USA, LLC | d3147f2d-1a72-4923-874b-8fdee2be625e | 2021-09-30 | Warnings, Adverse reactions | 71WO621TJD |
| Vancomycin Hydrochloride | VANCOMYCIN HYDROCHLORIDE | Mylan Institutional LLC | ce139a51-0471-4c31-b456-2f889f18dd2b | 2021-09-15 | Warnings, Adverse reactions | 71WO621TJD |
| Vancomycin Hydrochloride | VANCOMYCIN HYDROCHLORIDE | Hikma Pharmaceuticals USA Inc. | 2f5d3131-8ddc-43a5-91f7-947c531796e7 | 2021-06-02 | Warnings, Adverse reactions | 71WO621TJD |
| Vancomycin Hydrochloride | VANCOMYCIN HYDROCHLORIDE | Mylan Institutional LLC | 2dc7b3d6-3874-40ac-b8aa-7bcfe2dc0cdf | 2021-06-01 | Warnings, Adverse reactions | 71WO621TJD |
| vancomycin hydrochloride | VANCOMYCIN HYDROCHLORIDE | Mylan Institutional LLC | 3843d0d7-f70a-4b29-9478-dfb45b02425e | 2021-06-01 | Warnings, Adverse reactions | 71WO621TJD |
| Vancomycin Hydrochloride | VANCOMYCIN HYDROCHLORIDE | SAMSON MEDICAL TECHNOLOGIES LLC | 93589e71-3a11-4797-9176-8abdb7674a87 | 2020-11-29 | Boxed warning, Warnings, Adverse reactions | 71WO621TJD |
| Vancomycin Hydrochloride | VANCOMYCIN HYDROCHLORIDE | Fresenius Kabi, LLC | a7e7d990-1d74-459b-ac07-d1c3e13b3204 | 2019-01-09 | Warnings, Adverse reactions | 71WO621TJD |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.